Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil

References

• HardoonSLWhincupPHLennonLTWannametheeSGCapewellSMorrisRWHow much of the recent decline in the incidence of myocardial infarction in British men can be explained by changes in cardiovascular risk factors? Evidence from a prospective population-based studyCirculation2008117559860418212284
   PubMed Web of Science ®Google Scholar
• KahnRRobertsonRMSmithREddyDThe impact of prevention on reducing the burden of cardiovascular diseaseCirculation2008118557658518606915
   PubMed Web of Science ®Google Scholar
• PerkovicVHuxleyRWuYPrabhakaranDMacMahonSThe burden of blood pressure-related disease: a neglected priority for global healthHypertension200750699199717954719
   PubMed Web of Science ®Google Scholar
• CoreshJSelvinEStevensLAPrevalence of chronic kidney disease in the United StatesJAMA2007298172038204717986697
   PubMed Web of Science ®Google Scholar
• FoxCSCoadySSorliePDIncreasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart StudyCirculation2007115121544155017353438
   PubMed Web of Science ®Google Scholar
• KestenbaumBRudserKDde BoerIHDifferences in kidney function and incident hypertension: The Multi-Ethnic Study of AtherosclerosisAnn Intern Med2008148750150818378946
   PubMed Web of Science ®Google Scholar
• MunzelTSinningCPostFWarnholtzASchulzEPathophysiology, diagnosis and prognostic implications of endothelial dysfunctionAnn Med200840318019618382884
   PubMed Web of Science ®Google Scholar
• PahkalaKHeinonenOJLagstromHVascular endothelial function and leisure-time physical activity in adolescentsCirculation2008118232353235919015403
   PubMedGoogle Scholar
• HalcoxJPSchenkeWHZalosGPrognostic value of coronary vascular endothelial dysfunctionCirculation2002106665365812163423
   PubMed Web of Science ®Google Scholar
• LorenzMWMarkusHSBotsMLRosvallMSitzerMPrediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysisCirculation2007115445946717242284
   PubMed Web of Science ®Google Scholar
• McAllisterASAtkinsonABJohnstonGDHaddenDRBellPMMcCanceDRBasal nitric oxide production is impaired in offspring of patients with essential hypertensionClin Sci (Lond)199997214114710409468
   PubMed Web of Science ®Google Scholar
• SchlaichMPParnellMMAhlersBAImpaired L-arginine transport and endothelial function in hypertensive and genetically predisposed normotensive subjectsCirculation2004110243680368615569830
   PubMedGoogle Scholar
• YangZVenardosKJonesEMorrisBJChin-DustingJKayeDMIdentification of a novel polymorphism in the 3’UTR of the L-arginine transporter gene SLC7A1: contribution to hypertension and endothelial dysfunctionCirculation2007115101269127417325243
   PubMedGoogle Scholar
• ZhangCThe role of inflammatory cytokines in endothelial dysfunctionBasic Res Cardiol2008103539840618600364
   PubMed Web of Science ®Google Scholar
• FerrarioCMRichmondRSSmithRLevyPStrawnWBKivlighnSRenin-angiotensin system as a therapeutic target in managing atherosclerosisAm J Ther2004111445314704595
   PubMedGoogle Scholar
• FerrarioCMStrawnWBRole of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular diseaseAm J Cardiol200698112112816784934
   PubMed Web of Science ®Google Scholar
• StrawnWBDeanRHFerrarioCMNovel mechanisms linking angiotensin II and early atherogenesisJ Renin Angiotensin Aldosterone Syst200011111711967786
   PubMedGoogle Scholar
• StrawnWBFerrarioCMMechanisms linking angiotensin II and atherogenesisCurr Opin Lipidol200213550551212352014
   PubMedGoogle Scholar
• HumphreyJDMechanisms of arterial remodeling in hypertension: coupled roles of wall shear and intramural stressHypertension200852219520018541735
   PubMed Web of Science ®Google Scholar
• AbuissaHJonesPGMarsoSPO’KeefeJHJrAngiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trialsJ Am Coll Cardiol200546582182616139131
   PubMed Web of Science ®Google Scholar
• SchuppMClemenzMGinesteRMolecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activityDiabetes200554123442345216306360
   PubMed Web of Science ®Google Scholar
• SchuppMLeeLDFrostNRegulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolitesHypertension200647358658916365190
   PubMedGoogle Scholar
• EngeliSBohnkeJGorzelniakKWeight loss and the renin-angiotensin-aldosterone systemHypertension200545335636215630041
   PubMedGoogle Scholar
• EngeliSSchlingPGorzelniakKThe adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?Int J Biochem Cell Biol200335680782512676168
   PubMed Web of Science ®Google Scholar
• SharmaAMIs there a rationale for angiotensin blockade in the management of obesity hypertension?Hypertension2004441121915173127
   PubMedGoogle Scholar
• SharmaAMEngeliSThe role of renin-angiotensin system blockade in the management of hypertension associated with the cardiometabolic syndromeJ Cardiometab Syndr200611293517675902
   PubMedGoogle Scholar
• VaragicJTraskAJJessupJAChappellMCFerrarioCMNew angiotensinsJ Mol Med200886666367118437333
   PubMed Web of Science ®Google Scholar
• ImanishiTHanoTNishioIAngiotensin II accelerates endothelial progenitor cell senescence through induction of oxidative stressJ Hypertens20052319710415643130
   PubMed Web of Science ®Google Scholar
• VasaMFichtlschererSAicherANumber and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery diseaseCirc Res2001891E1E711440984
   PubMed Web of Science ®Google Scholar
• StrawnWBChappellMCDeanRHKivlighnSFerrarioCMInhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemiaCirculation2000101131586159310747353
   PubMed Web of Science ®Google Scholar
• WassmannSCzechTvan EickelsMFlemingIBohmMNickenigGInhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout miceCirculation2004110193062306715277329
   PubMed Web of Science ®Google Scholar
• RichmondRSTallantEAGallagherPEFerrarioCMStrawnWBAngiotensin II stimulates arachidonic acid release from bone marrow stromal cellsJ Renin Angiotensin Aldosterone Syst20045417618215803435
   PubMedGoogle Scholar
• StrawnWBRichmondRSAnn TallantEGallagherPEFerrarioCMRenin-angiotensin system expression in rat bone marrow haematopoietic and stromal cellsBr J Haematol2004126112012615198742
   PubMed Web of Science ®Google Scholar
• StrawnWBFerrarioCMAngiotensin II AT1 receptor blockade normalizes CD11b+ monocyte production in bone marrow of hypercholesterolemic monkeysAtherosclerosis2008196262463217692319
   PubMedGoogle Scholar
• SantosRASimoes e SilvaACMaricCAngiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor MasProc Natl Acad Sci U S A2003100148258826312829792
   PubMed Web of Science ®Google Scholar
• SantosRACastroCHGavaEImpairment of in vitro and in vivo heart function in angiotensin-(1–7) receptor MAS knockout miceHypertension2006475996100216567589
   PubMedGoogle Scholar
• CastroCHSantosRAFerreiraAJBaderMAleninaNAlmeidaAPEvidence for a functional interaction of the angiotensin-(1–7) receptor Mas with AT1 and AT2 receptors in the mouse heartHypertension200546493794216157793
   PubMedGoogle Scholar
• Dias-PeixotoMFSantosRAGomesERMolecular mechanisms involved in the angiotensin-(1–7)/Mas signaling pathway in cardiomyocytesHypertension200852354254818695148
   PubMed Web of Science ®Google Scholar
• GallagherPEFerrarioCMTallantEAMAP Kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptidesAm J Physiol Cell Physiol20082955C1169C117418768926
   PubMedGoogle Scholar
• SampaioWOHenrique de CastroCSantosRASchiffrinELTouyzRMAngiotensin-(1–7) counterregulates angiotensin II signaling in human endothelial cellsHypertension20075061093109817984366
   PubMed Web of Science ®Google Scholar
• CrackowerMASaraoROuditGYAngiotensin-converting enzyme 2 is an essential regulator of heart functionNature2002417689182282812075344
   PubMed Web of Science ®Google Scholar
• FerrarioCMAngiotensin-converting enzyme 2 and angiotensin-(1–7): an evolving story in cardiovascular regulationHypertension200647351552116365192
   PubMedGoogle Scholar
• LuHRateriDLFeldmanDLRenin inhibition reduces hypercholesterolemia-induced atherosclerosis in miceJ Clin Invest2008118398499318274671
   PubMedGoogle Scholar
• BrennerBMCooperMEde ZeeuwDEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyN Engl J Med20013451286186911565518
   PubMed Web of Science ®Google Scholar
• CohnJNTognoniGA randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failureN Engl J Med2001345231667167511759645
   PubMed Web of Science ®Google Scholar
• DicksteinKKjekshusJEffects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist LosartanLancet2002360933575276012241832
   PubMed Web of Science ®Google Scholar
• LewisEJHunsickerLGClarkeWRRenoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetesN Engl J Med20013451285186011565517
   PubMed Web of Science ®Google Scholar
• ParvingHHLehnertHBrochner-MortensenJGomisRAndersenSArnerPThe effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetesN Engl J Med20013451287087811565519
   PubMed Web of Science ®Google Scholar
• PfefferMAMcMurrayJJVelazquezEJValsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothN Engl J Med2003349201893190614610160
   PubMed Web of Science ®Google Scholar
• PfefferMASwedbergKGrangerCBEffects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeLancet2003362938675976613678868
   PubMed Web of Science ®Google Scholar
• The_ONTARGET_Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med20083581547155918378520
   PubMed Web of Science ®Google Scholar
• StrawnWBFerrarioCMTallantEAAngiotensin-(1–7) reduces smooth muscle growth after vascular injuryHypertension199933(1 Pt 2):2072119931106
   PubMedGoogle Scholar
• IshiyamaYGallagherPEAverillDBTallantEABrosnihanKBFerrarioCMUpregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptorsHypertension200443597097615007027
   PubMed Web of Science ®Google Scholar
• FerrarioCMTraskAJJessupJAAdvances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1–7) in regulation of cardiovascular functionAm J Physiol Heart Circ Physiol20052896H2281H229016055515
   PubMed Web of Science ®Google Scholar
• IgaseMStrawnWBGallagherPEGearyRLFerrarioCMAngiotensin II AT1 receptors regulate ACE2 and angiotensin-(1–7) expression in the aorta of spontaneously hypertensive ratsAm J Physiol Heart Circ Physiol20052893H1013H101915833808
   PubMed Web of Science ®Google Scholar
• TallantEAFerrarioCMGallagherPEAngiotensin-(1–7) inhibits growth of cardiac myocytes through activation of the mas receptorAm J Physiol Heart Circ Physiol20052894H1560H156615951342
   PubMedGoogle Scholar
• YokoyamaHAverillDBBrosnihanKBSmithRDSchiffrinELFerrarioCMRole of blood pressure reduction in prevention of cardiac and vascular hypertrophyAm J Hypertens200518792292916053988
   PubMedGoogle Scholar
• AgataJUraNYoshidaHOlmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzymeHypertens Res2006291186587417345786
   PubMed Web of Science ®Google Scholar
• TraskAJAverillDBGantenDChappellMCFerrarioCMPrimary role of angiotensin-converting enzyme-2 in cardiac production of angiotensin-(1–7) in transgenic Ren-2 hypertensive ratsAm J Physiol Heart Circ Physiol20072926H3019H302417308000
   PubMedGoogle Scholar
• TraskAJFerrarioCMAngiotensin-(1–7): pharmacology and new perspectives in cardiovascular treatmentsCardiovasc Drug Rev200725216217417614938
   PubMedGoogle Scholar
• GallagherPEFerrarioCMTallantEARegulation of ACE2 in cardiac myocytes and fibroblastsAm J Physiol Heart Circ Physiol20082956H2373H237918849338
   PubMed Web of Science ®Google Scholar
• IgaseMKoharaKNagaiTMikiTFerrarioCMIncreased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockadeHypertens Res200831355355918497476
   PubMedGoogle Scholar
• FliserDBuchholzKHallerHAntiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammationCirculation200411091103110715313950
   PubMed Web of Science ®Google Scholar
• BahlmannFHde GrootKMuellerOHertelBHallerHFliserDStimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonistsHypertension200545452652915767470
   PubMedGoogle Scholar
• StumpeKAgabiti-RoseiEZielinskiTCarotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The multicentre olmesartan atherosclerosis regresssion evaluation (MORE) studyTher Adv Cardiovasc Dis2007129710619124398
   PubMedGoogle Scholar
• NayaMTsukamotoTMoritaKOlmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patientsJ Am Coll Cardiol200750121144114917868805
   PubMed Web of Science ®Google Scholar
• SmithRYokoyamaHAverillDBSchiffrinELFerrarioCMReversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptorsJASH200823165172
   Google Scholar
• SmithRDYokoyamaHAverillDBThe protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristicsAm J Cardiovasc Drugs20066533534217083268
   PubMedGoogle Scholar
• YamamotoEDongYFKataokaKOlmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibitionHypertension200852357358018678790
   PubMed Web of Science ®Google Scholar
• IzumiyaYKimSIzumiYApoptosis signal-regulating kinase 1 plays a pivotal role in angiotensin II-induced cardiac hypertrophy and remodelingCirc Res200393987488314551246
   PubMed Web of Science ®Google Scholar
• PorteriERodellaLRizzoniDEffects of olmesartan and enalapril at low or high doses on cardiac, renal and vascular interstitial matrix in spontaneously hypertensive ratsBlood Press200514318419216036499
   PubMed Web of Science ®Google Scholar
• YoshidaJYamamotoKManoTAT1 receptor blocker added to ACE inhibitor provides benefits at advanced stage of hypertensive diastolic heart failureHypertension200443368669114757777
   PubMedGoogle Scholar
• MiyazakiMTakaiSAnti-atherosclerotic efficacy of olmesartanJ Hum Hypertens200216Suppl 2S7S1211967727
   PubMedGoogle Scholar
• TakaiSJinDSakaguchiMMuramatsuMMiyazakiMThe regressive effect of an angiotensin II receptor blocker on formed fatty streaks in monkeys fed a high-cholesterol dietJ Hypertens200523101879188616148612
   PubMed Web of Science ®Google Scholar
• KatoMSadaTMizunoMKitayamaKInabaTKoikeHEffect of combined treatment with an angiotensin II receptor antagonist and an HMG-CoA reductase inhibitor on atherosclerosis in genetically hyperlipidemic rabbitsJ Cardiovasc Pharmacol200546455656216160612
   PubMedGoogle Scholar
• van der HoornJWKleemannRHavekesLMKooistraTPrincenHMJukemaJWOlmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic miceJ Hypertens200725122454246217984667
   PubMedGoogle Scholar
• YamamotoEYamashitaTTanakaTPravastatin enhances beneficial effects of olmesartan on vascular injury of salt-sensitive hypertensive rats, via pleiotropic effectsArterioscler Thromb Vasc Biol200727355656317170375
   PubMedGoogle Scholar
• TsudaMIwaiMLiJMInhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stressHypertension200545454555115723967
   PubMedGoogle Scholar
• KatoMSadaTChumaHSeverity of hyperlipidemia does not affect antiatherosclerotic effect of an angiotensin II receptor antagonist in apolipoprotein E-deficient miceJ Cardiovasc Pharmacol200647676476916810077
   PubMedGoogle Scholar
• KogaKYamagishiSTakeuchiMCS-886, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty ratsMol Med200281059159912477969
   PubMed Web of Science ®Google Scholar
• KoboriHOzawaYSuzakiYNishiyamaAEnhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive ratsJ Am Soc Nephrol20051672073208015888567
   PubMed Web of Science ®Google Scholar
• NangakuMMiyataTSadaTAnti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat modelJ Am Soc Nephrol20031451212122212707391
   PubMedGoogle Scholar
• IzuharaYNangakuMInagiRRenoprotective properties of angiotensin receptor blockers beyond blood pressure loweringJ Am Soc Nephrol200516123631364116236804
   PubMed Web of Science ®Google Scholar
• NakamuraHInoueTArakawaNPharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy modelsEur J Pharmacol200551223239246
   Google Scholar
• JinnoTIwaiMLiZCalcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartanHypertension200443226326914707152
   PubMed Web of Science ®Google Scholar
• LiuHWIwaiMTakeda-MatsubaraYEffect of estrogen and AT1 receptor blocker on neointima formationHypertension200240445145712364346
   PubMedGoogle Scholar
• MinLJMogiMLiJMIwanamiJIwaiMHoriuchiMAldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cellsCirc Res200597543444216081869
   PubMedGoogle Scholar
• MukaiYShimokawaHHigashiMInhibition of renin-angiotensin system ameliorates endothelial dysfunction associated with aging in ratsArterioscler Thromb Vasc Biol20022291445145012231564
   PubMedGoogle Scholar
• FerrarioCMThe role of angiotensin antagonism in stroke prevention in patients with hypertension: focus on losartanCurr Med Res Opin200420111797180415537480
   PubMed Web of Science ®Google Scholar
• FabiaMJAbdillaNOltraRFernandezCRedonJAntihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoringJ Hypertens20072571327133617563549
   PubMed Web of Science ®Google Scholar
• KoikeHSadaTMizunoMIn vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonistJ Hypertens Suppl2001191S3S1411451212
   PubMedGoogle Scholar
• YanagisawaHAmemiyaYKanazakiTNonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compoundsJ Med Chem19963913233388568823
   PubMed Web of Science ®Google Scholar
• LeMTPugsleyMKVauquelinGVan LiefdeIMolecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptorBr J Pharmacol2007151795296217572702
   PubMed Web of Science ®Google Scholar
• IchikawaSTakayamaYLong-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patientsHypertens Res200124664164611768722
   PubMedGoogle Scholar
• SchindlerCBrosnihanKBFerrarioCMComparison of inhibitory effects of irbesartan and atorvastatin treatment on the renin angiotensin system (RAS) in veins: a randomized double-blind crossover trial in healthy subjectsJ Clin Pharmacol200747111212017192509
   PubMedGoogle Scholar
• IyerSNAverillDBChappellMCYamadaKAllredAJFerrarioCMContribution of angiotensin-(1–7) to blood pressure regulation in salt-depleted hypertensive ratsHypertension200036341742210988275
   PubMedGoogle Scholar
• MoriguchiATallantEAMatsumuraKOpposing actions of angiotensin-(1–7) and angiotensin II in the brain of transgenic hypertensive ratsHypertension1995256126012657768571
   PubMedGoogle Scholar
• Campagnole-SantosMJHeringerSBBatistaENKhoslaMCSantosRADifferential baroreceptor reflex modulation by centrally infused angiotensin peptidesAm J Physiol1992263(1 Pt 2):R89R941636797
   PubMedGoogle Scholar
• GrobeJLMeccaAPLingisMPrevention of angiotensin II-induced cardiac remodeling by angiotensin-(1–7)Am J Physiol Heart Circ Physiol20072922H736H74217098828
   PubMed Web of Science ®Google Scholar
• FerreiraAJSantosRAAlmeidaAPAngiotensin-(1–7): cardioprotective effect in myocardial ischemia/reperfusionHypertension200138(3 Pt 2): 66566811566952
   PubMed Web of Science ®Google Scholar
• FerreiraAJSantosRAAlmeidaAPAngiotensin-(1–7) improves the post-ischemic function in isolated perfused rat heartsBraz J Med Biol Res20023591083109012219180
   PubMedGoogle Scholar
• DelliPizziAMHilcheySDBell-QuilleyCPNatriuretic action of angiotensin(1–7)Br J Pharmacol19941111138012686
   PubMed Web of Science ®Google Scholar
• HellerJKramerHJMalyJCervenkaLHoracekVEffect of intrarenal infusion of angiotensin-(1–7) in the dogKidney Blood Press Res2000232899410765110
   PubMedGoogle Scholar
• VallonVHeyneNRichterKKhoslaMCFechterK[7-D-ALA]-angiotensin 1–7 blocks renal actions of angiotensin 1–7 in the anesthetized ratJ Cardiovasc Pharmacol19983211641679676737
   PubMed Web of Science ®Google Scholar
• LootAERoksAJHenningRHAngiotensin-(1–7) attenuates the development of heart failure after myocardial infarction in ratsCirculation2002105131548155011927520
   PubMedGoogle Scholar
• FerrarioCMMartellNYunisCCharacterization of angiotensin-(1–7) in the urine of normal and essential hypertensive subjectsAm J Hypertens19981121371469524041
   PubMedGoogle Scholar
• LuqueMMartinPMartellNFernandezCBrosnihanKBFerrarioCMEffects of captopril related to increased levels of prostacyclin and angiotensin-(1–7) in essential hypertensionJ Hypertens19961467998058793704
   PubMed Web of Science ®Google Scholar
• FerrarioCMSmithRDBrosnihanBEffects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertensionAm J Hypertens200215655756412074359
   PubMedGoogle Scholar
• SchmeiderREHilgersKFSchlaichMPRenin-angiotensin system and cardiovascular riskLancet20073691208121917416265
   PubMed Web of Science ®Google Scholar